UY32971A - Proteínas de unión al antígeno de la il-23 humana - Google Patents

Proteínas de unión al antígeno de la il-23 humana

Info

Publication number
UY32971A
UY32971A UY0001032971A UY32971A UY32971A UY 32971 A UY32971 A UY 32971A UY 0001032971 A UY0001032971 A UY 0001032971A UY 32971 A UY32971 A UY 32971A UY 32971 A UY32971 A UY 32971A
Authority
UY
Uruguay
Prior art keywords
human
proteins
antigen
union
antigen binding
Prior art date
Application number
UY0001032971A
Other languages
English (en)
Inventor
Jennifer E Towne
Janet D Cheng
Zhang Yu
Sun Yu
Cerne Heather
Derek E Piper
Randal R Ketchem
Jason C O Neill
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43413789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32971(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY32971A publication Critical patent/UY32971A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Se proporcionan proteínas de unión al antígeno que se unen a la IL-23 humana. Asimismo, se proporcionan ácidos nucleicos que codifican la proteína de unión al antígeno, vectores y células que los codifican, así como el uso de las proteínas de unión al antígeno de la IL-23 para fines de diagnóstico y terapia
UY0001032971A 2009-10-26 2010-10-26 Proteínas de unión al antígeno de la il-23 humana UY32971A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25498209P 2009-10-26 2009-10-26
US38128710P 2010-09-09 2010-09-09

Publications (1)

Publication Number Publication Date
UY32971A true UY32971A (es) 2010-11-30

Family

ID=43413789

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032971A UY32971A (es) 2009-10-26 2010-10-26 Proteínas de unión al antígeno de la il-23 humana

Country Status (37)

Country Link
US (9) US8722033B2 (es)
EP (3) EP2493925B1 (es)
JP (5) JP5930968B2 (es)
KR (3) KR101568461B1 (es)
CN (3) CN104761642A (es)
AR (1) AR078778A1 (es)
AU (1) AU2010315557B2 (es)
BR (2) BR112012009854B8 (es)
CA (2) CA3030092C (es)
CL (1) CL2012001096A1 (es)
CO (1) CO6531481A2 (es)
CR (1) CR20120210A (es)
CY (1) CY1118576T1 (es)
EA (1) EA025366B1 (es)
ES (1) ES2613236T3 (es)
HK (2) HK1177469A1 (es)
HR (1) HRP20170037T1 (es)
HU (1) HUE030871T2 (es)
IL (3) IL219241A (es)
JO (1) JO3244B1 (es)
LT (1) LT2493925T (es)
MA (1) MA33757B1 (es)
MX (1) MX358249B (es)
MY (1) MY156286A (es)
NZ (2) NZ599875A (es)
PE (2) PE20161327A1 (es)
PL (1) PL2493925T3 (es)
PT (1) PT2493925T (es)
RS (1) RS55666B1 (es)
SG (2) SG10202103260TA (es)
SI (1) SI2493925T1 (es)
TN (1) TN2012000167A1 (es)
TW (2) TW201417830A (es)
UA (1) UA113609C2 (es)
UY (1) UY32971A (es)
WO (1) WO2011056600A1 (es)
ZA (1) ZA201203058B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
RS55161B1 (sr) 2010-11-04 2017-01-31 Boehringer Ingelheim Int Anti-il-23 antitela
US9012161B2 (en) * 2011-01-25 2015-04-21 Monell Chemical Senses Center Methods of identifying molecules that provide or enhance sweet taste
EP2583979B1 (en) * 2011-10-19 2015-12-16 Effimune Methods to prepare antibodies directed against p19 subunit of human IL-23
NZ700802A (en) * 2012-05-03 2017-06-30 Boehringer Ingelheim Int Anti-il-23p19 antibodies
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
EP2968488A1 (en) * 2013-03-15 2016-01-20 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
EP2968486A1 (en) * 2013-03-15 2016-01-20 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
MA39847A (fr) 2014-04-15 2017-02-22 Sorrento Therapeutics Inc Protéines de liaison à l'antigène se liant à wisp1
WO2015179918A1 (en) 2014-05-27 2015-12-03 The University Of Queensland Modulation of cellular stress
AU2015289874A1 (en) 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
TWI711629B (zh) 2014-09-03 2020-12-01 德商包林格因蓋爾漢國際股份有限公司 靶向IL-23A與TNF-α之化合物及其用途
CN108290058B (zh) 2015-09-17 2023-05-16 美国安进公司 使用il23途径生物标志物预测il23拮抗剂的临床应答
TWI811716B (zh) * 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
EA201891002A1 (ru) * 2015-10-19 2018-11-30 Дайэкс Корп. Иммунологический анализ для определения расщепленного высокомолекулярного кининогена
WO2017112536A1 (en) 2015-12-22 2017-06-29 Amgen Inc. Ccl20 as a predictor of clinical response to il23-antagonists
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2019023812A1 (en) * 2017-08-04 2019-02-07 The Hospital For Sick Children VACCINE COMPOSITION AGAINST MALARIA AND METHOD THEREOF
WO2019023811A1 (en) * 2017-08-04 2019-02-07 The Hospital For Sick Children NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY
TWI744617B (zh) 2018-03-30 2021-11-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
KR20210032441A (ko) 2018-07-13 2021-03-24 아스트라제네카 콜라보레이션 벤처스, 엘엘씨 브라지쿠맙을 이용한 궤양성 대장염의 치료
US20200385453A1 (en) * 2019-06-04 2020-12-10 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
JP2022539527A (ja) * 2019-06-26 2022-09-12 エーピー バイオサイエンシーズ， インコーポレイテッド Ｔ細胞活性化のための抗体
WO2021126435A1 (en) 2019-12-20 2021-06-24 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
CN111718414B (zh) * 2020-06-12 2021-03-02 江苏荃信生物医药有限公司 抗人白介素23单克隆抗体及其应用
WO2022041390A1 (zh) * 2020-08-28 2022-03-03 江苏荃信生物医药股份有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂及其制备方法
TW202224702A (zh) 2020-09-10 2022-07-01 美商美國禮來大藥廠 治療性抗體調配物
CN113156134B (zh) * 2020-11-26 2024-01-23 江苏荃信生物医药股份有限公司 用于检测人白介素23的elisa试剂盒及检测方法
US20220373539A1 (en) * 2021-05-24 2022-11-24 Amgen Inc. Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
KR20240025524A (ko) * 2021-06-25 2024-02-27 상가모 테라퓨틱스, 인코포레이티드 Il-23r에 특이적인 항원 결합제 및 이의 용도
WO2023056417A1 (en) 2021-09-30 2023-04-06 Eli Lilly And Company Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis
CN114994331B (zh) * 2022-05-17 2023-02-24 无锡科金生物科技有限公司 一种检测蛋白表达水平的试剂盒及其制备方法和应用
WO2024077113A1 (en) 2022-10-06 2024-04-11 Eli Lilly And Company Methods of treating fatigue in ulcerative colitis

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH06508035A (ja) 1991-06-14 1994-09-14 ディーエヌエックス　コーポレーション トランスジェニックブタにおけるヒトヘモグロビンの生産
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
SG47979A1 (en) 1991-11-14 1998-04-17 Charles Weissman Transgenic animals lacking prion proteins
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994010308A1 (en) 1992-10-23 1994-05-11 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CO4810232A1 (es) 1997-07-25 1999-06-30 Schering Corp Citoquinas de mamiferos y sus secuencias codificadoras
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
JP4124573B2 (ja) 1998-03-17 2008-07-23 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する炎症性腸疾患の予防又は治療剤
AU3170199A (en) 1998-04-14 1999-11-08 Chugai Research Institute For Molecular Medicine, Inc. Novel cytokine-like protein
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US20120288494A1 (en) 1999-03-25 2012-11-15 Abbott Laboratories Anti-IL-12/IL-23 antibodies and uses thereof
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
WO2001018051A2 (en) 1999-09-09 2001-03-15 Schering Corporation Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
NZ539271A (en) 2002-10-30 2008-12-24 Genentech Inc Inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23)
EP1587834B1 (en) 2002-12-23 2011-07-06 Schering Corporation Uses of il-23 mammalian cytokine; related reagents
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
WO2004081190A2 (en) 2003-03-10 2004-09-23 Schering Corporation Uses of il-23 agonists and antagonists; related reagents
CN101052726A (zh) 2003-05-09 2007-10-10 森托科尔公司 IL－23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
MXPA06012754A (es) 2004-05-03 2007-02-19 Schering Corp El uso de la expresion de il-17 para predecir la inflamacion de la piel: metodos de tratamiento.
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
EP2292758A3 (en) 2004-12-20 2013-12-25 Merck Sharp & Dohme Corp. Uses of mammalian cytokine; related reagents
CN101120087A (zh) 2004-12-21 2008-02-06 森托科尔公司 抗-il-12抗体、表位、组合物、方法和用途
EP1907421A4 (en) 2005-06-30 2012-03-28 Abbott Lab IL-12 / P40 BINDING PROTEINS
JP2009501006A (ja) 2005-06-30 2009-01-15 セントカー・インコーポレーテツド 抗ｉｌ−２３抗体、組成物、方法および用途
DK1937721T3 (da) 2005-08-25 2010-10-18 Lilly Co Eli Anti-IL-23 antistoffer
DK1931710T3 (en) 2005-08-31 2017-04-03 Merck Sharp & Dohme CONSTRUCTED ANTI-IL-23 ANTIBODIES
CN1955248B (zh) * 2005-10-28 2011-10-12 安集微电子（上海）有限公司 钽阻挡层用化学机械抛光浆料
US20090270480A1 (en) 2005-12-28 2009-10-29 Bernard Amegadzie Markers and Methods for Assessing and Treating Psoriasis and Related Disorders
PL1971366T3 (pl) 2005-12-29 2015-01-30 Janssen Biotech Inc Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
CA2655372A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
KR20150038227A (ko) * 2007-01-16 2015-04-08 애브비 인코포레이티드 건선의 치료방법
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
CA2678863A1 (en) 2007-02-23 2008-08-28 Schering Corporation Engineered anti-il-23p19 antibodies
NZ579158A (en) * 2007-02-23 2012-01-12 Schering Corp Engineered anti-il-23p19 antibodies
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
EP2215125A1 (en) 2007-11-27 2010-08-11 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
US8178092B2 (en) 2008-03-18 2012-05-15 Abbott Laboratories Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
CA2733642A1 (en) 2008-08-14 2010-02-18 Cephalon Australia Pty Ltd Anti-il-12/il-23 antibodies
CN102202655B (zh) 2008-08-27 2013-06-19 默沙东公司 基因工程抗IL-23p19抗体的冻干制剂
US20120128689A1 (en) 2009-04-01 2012-05-24 Glaxo Group Limited Anti-il-23 immunoglobulins
US20120027799A1 (en) 2009-04-02 2012-02-02 The Johns Hopkins University Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer
US20120264917A1 (en) 2009-05-27 2012-10-18 Ablynx N.V. Biparatopic protein constructs directed against il-23
RU2012114854A (ru) 2009-09-14 2013-10-27 Эбботт Лэборетриз Способы лечения псориаза
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PE20121691A1 (es) 2010-01-15 2012-12-14 Kirin Amgen Inc Formulacion de anticuerpos y regimenes terapeuticos
JP2013520426A (ja) 2010-02-18 2013-06-06 ブリストル−マイヤーズ スクイブ カンパニー Ｉｌ−２３に結合する、フィブロネクチンをベースとする足場ドメインタンパク質
WO2012009760A1 (en) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
TW201233395A (en) 2010-10-06 2012-08-16 Abbott Lab Methods for treating psoriasis
CN107029234A (zh) 2010-10-08 2017-08-11 诺华有限公司 利用il‑17拮抗剂治疗牛皮癣的方法
RS55161B1 (sr) 2010-11-04 2017-01-31 Boehringer Ingelheim Int Anti-il-23 antitela

Also Published As

Publication number Publication date
MA33757B1 (fr) 2012-11-01
EP2493925B1 (en) 2016-11-23
US20200181255A1 (en) 2020-06-11
IL244801A0 (en) 2016-04-21
JP2016102122A (ja) 2016-06-02
KR101568461B1 (ko) 2015-11-12
MX2012004868A (es) 2012-08-03
BR112012009854B1 (pt) 2020-12-15
EP3656790A1 (en) 2020-05-27
TW201417830A (zh) 2014-05-16
US20140212428A1 (en) 2014-07-31
ZA201203058B (en) 2013-01-30
PL2493925T3 (pl) 2017-09-29
SI2493925T1 (sl) 2017-05-31
KR20140062186A (ko) 2014-05-22
EA201270571A1 (ru) 2012-09-28
KR20120090091A (ko) 2012-08-16
CN110407936A (zh) 2019-11-05
US20190322737A1 (en) 2019-10-24
CL2012001096A1 (es) 2012-09-28
JP2018117626A (ja) 2018-08-02
AR078778A1 (es) 2011-11-30
BR112012009854A8 (pt) 2019-10-08
EP2493925A1 (en) 2012-09-05
AU2010315557B2 (en) 2014-02-27
IL219241A0 (en) 2012-06-28
US20170002070A1 (en) 2017-01-05
CN102741285B (zh) 2015-03-25
TN2012000167A1 (en) 2013-12-12
US20190071498A1 (en) 2019-03-07
IL274871A (en) 2020-07-30
IL219241A (en) 2016-03-31
EP3181586A1 (en) 2017-06-21
EA025366B1 (ru) 2016-12-30
JO3244B1 (ar) 2018-03-08
JP2020018308A (ja) 2020-02-06
CY1118576T1 (el) 2017-07-12
CO6531481A2 (es) 2012-09-28
CA2778112A1 (en) 2011-05-12
JP7278355B2 (ja) 2023-05-19
NZ625630A (en) 2016-09-30
JP7023908B2 (ja) 2022-02-22
KR20160118278A (ko) 2016-10-11
SG10201800682SA (en) 2018-03-28
MY156286A (en) 2016-01-29
PE20121579A1 (es) 2012-12-13
JP5930968B2 (ja) 2016-06-08
MX358249B (es) 2018-08-10
UA113609C2 (xx) 2017-02-27
AU2010315557A1 (en) 2012-09-20
US9487580B2 (en) 2016-11-08
BR112012009854A2 (pt) 2016-11-22
US20210024626A1 (en) 2021-01-28
CA3030092C (en) 2023-12-19
US9951129B2 (en) 2018-04-24
TWI432210B (zh) 2014-04-01
CA2778112C (en) 2019-02-26
ES2613236T3 (es) 2017-05-23
JP2013507991A (ja) 2013-03-07
HRP20170037T1 (hr) 2017-03-10
JP2022033730A (ja) 2022-03-02
HK1212357A1 (en) 2016-06-10
TW201121567A (en) 2011-07-01
CA3030092A1 (en) 2011-05-12
PT2493925T (pt) 2017-02-14
IL244801B (en) 2020-05-31
CR20120210A (es) 2012-07-20
LT2493925T (lt) 2017-04-25
KR101652609B1 (ko) 2016-08-30
CN104761642A (zh) 2015-07-08
US8722033B2 (en) 2014-05-13
RS55666B1 (sr) 2017-06-30
SG10202103260TA (en) 2021-05-28
BR122020002402B8 (pt) 2022-03-29
PE20161327A1 (es) 2016-12-03
US20220056122A1 (en) 2022-02-24
HUE030871T2 (en) 2017-06-28
US20130004501A1 (en) 2013-01-03
NZ599875A (en) 2014-10-31
BR112012009854B8 (pt) 2021-05-25
BR122020002402B1 (pt) 2022-02-08
US20210230267A1 (en) 2021-07-29
CN102741285A (zh) 2012-10-17
WO2011056600A1 (en) 2011-05-12
HK1177469A1 (en) 2013-08-23

Similar Documents

Publication Publication Date Title
UY32971A (es) Proteínas de unión al antígeno de la il-23 humana
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
CR20150258A (es) Anticuerpos anti-ceacam5 y usos de éstos
PE20190229A1 (es) Anticuerpos anti-fcrn
CO7250445A2 (es) Proteínas de unión a antígeno st2
DOP2014000083A (es) Inmunoenlazadores dirigidos contra el tnf
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
UY35286A (es) Construcciones de anticuerpos para CDH19 y CD3
GT201300306A (es) Anticuerpos anti-angptl3 y usos de los mismos
AR070453A1 (es) Anticuerpos dirigidos a angiopoyetina -1 y angiopoyetina-2 y usos de los mismos
GT200900188A (es) Anticuerpos neutralizantes del citomegalovirus humano y su uso.
EA201400579A1 (ru) Антитела к il-36r
ECSP12012272A (es) Proteínas que se unen al tnf-?
CR11282A (es) Proteinas enlazadas al antigeno de celula de cepa mcdonough de felino humanas
UY31904A (es) Anticuerpos contra il-6 y sus usos
EA201490825A8 (ru) Tdp-43-специфически связывающие молекулы
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
CR20110400A (es) Proteinas de enlace al receptor cgrp humano
ECSP11011445A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b
DOP2014000199A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
AR080680A1 (es) Proteinas de union a basigina
UY35718A (es) Anticuerpos anti-csf-1r: métodos de expresión de los mismos.
AR121799A2 (es) Proteínas de unión a antígenos de il-23 humana
AR118080A2 (es) Proteínas de unión a antígeno dirigidas contra el receptor
EA201792665A1 (ru) Антитела против ctla-4 и способы их применения

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20200730